The ubiquitin-proteasome system and cancer

被引:45
作者
Devoy, A [1 ]
Soane, T [1 ]
Welchman, R [1 ]
Mayer, RJ [1 ]
机构
[1] Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England
来源
ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM | 2005年 / 41卷
基金
英国惠康基金;
关键词
D O I
10.1042/EB0410187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ubiquitin proteasome system (UPS) has emerged from obscurity to be seen as a major player in all regulatory processes in the cell. The concentrations of key proteins in diverse regulatory pathways are controlled by post-translational ubiquitination and degradation by the 26 S proteasome. These regulatory cascades include growth-factor-controlled signal-transduction pathways and multiple points in the cell cycle. The cell cycle is orchestrated by a combination of cyclin-dependent kinases, kinase inhibitors and protein phosphorylation, together with the timely and specific degradation of cyclins and kinase inhibitors at critical points in the cell cycle by the UPS. These processes provide the irreversibility needed for movement of the cycle through gap 1 (G(1)), DNA synthesis (S), gap 2 (G(2)) and mitosis (M). The molecular events include cell-size control, DNA replication, DNA repair, chromosomal rearrangements and cell division. It is doubtful whether these events could be achieved without the temporally and spatially regulated combination of protein phosphorylation and ubiquitin-dependent degradation of key cell-cycle regulatory proteins. The oncogenic transformation of cells is a multistep process that can be triggered by mutation of genes for proteins involved in regulatory processes from the cell surface to the nucleus. Since the UPS has critical functions at all these levels of control, it is to be expected that UPS activities will be central to cell transformation and cancer progression.
引用
收藏
页码:187 / 203
页数:17
相关论文
共 26 条
[1]   Advances in protein kinase B signalling:: AKTion on multiple fronts [J].
Brazil, DP ;
Yang, ZZ ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (05) :233-242
[2]   Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB [J].
Brummelkamp, TR ;
Nijman, SMB ;
Dirac, AMG ;
Bernards, R .
NATURE, 2003, 424 (6950) :797-801
[3]   The SCF ubiquitin ligase: Insights into a molecular machine [J].
Cardozo, T ;
Pagano, M .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (09) :739-751
[4]   Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein [J].
Corn, PG ;
McDonald, ER ;
Herman, JG ;
El-Deiry, WS .
NATURE GENETICS, 2003, 35 (03) :229-237
[5]   Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome [J].
Dawson, S ;
Apcher, S ;
Mee, M ;
Higashitsuji, H ;
Baker, R ;
Uhle, S ;
Dubiel, W ;
Fujita, J ;
Mayer, RJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :10893-10902
[6]   CYCLIN - A PROTEIN SPECIFIED BY MATERNAL MESSENGER-RNA IN SEA-URCHIN EGGS THAT IS DESTROYED AT EACH CLEAVAGE DIVISION [J].
EVANS, T ;
ROSENTHAL, ET ;
YOUNGBLOM, J ;
DISTEL, D ;
HUNT, T .
CELL, 1983, 33 (02) :389-396
[7]   SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? [J].
Gill, G .
GENES & DEVELOPMENT, 2004, 18 (17) :2046-2059
[8]   The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction [J].
Glickman, MH ;
Ciechanover, A .
PHYSIOLOGICAL REVIEWS, 2002, 82 (02) :373-428
[9]   Update on the proteasome inhibitor bortezomib in hematologic malignancies [J].
Goy, A ;
Gilles, F .
CLINICAL LYMPHOMA, 2004, 4 (04) :230-237
[10]   Skp2 is oncogenic and overexpressed in human cancers [J].
Gstaiger, M ;
Jordan, R ;
Lim, M ;
Catzavelos, C ;
Mestan, J ;
Slingerland, J ;
Krek, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) :5043-5048